Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.20452/pamw.17046 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The X-Age Project to construct a Chinese aging clock.
Nat Aging
September 2025
Aging Biomarker Consortium (ABC), Beijing, China.
The global surge in the population of people 60 years and older, including that in China, challenges healthcare systems with rising age-related diseases. To address this demographic change, the Aging Biomarker Consortium (ABC) has launched the X-Age Project to develop a comprehensive aging evaluation system tailored to the Chinese population. Our goal is to identify robust biomarkers and construct composite aging clocks that capture biological age, defined as an individual's physiological and molecular state, across diverse Chinese cohorts.
View Article and Find Full Text PDFBiosynthetic ε-poly-L-lysine for the treatment of extensively- and pan-drug-resistant Pseudomonas aeruginosa.
NPJ Antimicrob Resist
September 2025
Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Graduate Medical School, Singapore, Singapore.
Pseudomonas aeruginosa (PA) represents a major cause of antimicrobial resistance-related morbidity and mortality. The recent emergence of highly fatal infections, caused by carbapenem-resistant PA, has called for novel antimicrobial therapies and strategies. In this study, we highlight the therapeutic potential of ε-poly-L-lysine (εPL), an antimicrobial polymer for treating extensively-and pan-drug-resistant-PA.
View Article and Find Full Text PDFThe performance of an ophthalmic solution containing Poloxamer 407 and Polyquaternium 133 in reducing conjunctival bacterial load in patients receiving cataract surgery, a randomized trial.
Eur J Ophthalmol
September 2025
Department of Ophthalmology, Casilino General Hospital, Rome, Italy.
PurposeTo evaluate the safety and ability of an ophthalmic solution containing Poloxamer 407 and Polyquaternium 133 to reduce conjunctival bacterial load before cataract surgery.MethodsPatients (n = 74) were randomized to 2 groups: treatment (n = 37) or placebo (treatment's vehicle; (n = 37)) BID from V1 to V3. Patients were also given standard postoperative treatment from V2 to V3.
View Article and Find Full Text PDFFemtosecond Laser Flap-in-Flap Technique for Correction of Post-LASIK Myopic Regression.
J Refract Surg
September 2025
Purpose: To discuss the technique and outcome of what the authors called the "flap-in-flap" technique and report its safety as a procedure for correction of post-laser in situ keratomileusis (LASIK) myopic regression.
Methods: Seven eyes of 4 patients were included in this study. All patients had previously undergone LASIK for compound myopic astigmatism using the Moria M2 micro-keratome (Moria) 8 to 12 years prior to presentation.
Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration.
Acta Ophthalmol
September 2025
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.
Purpose: To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age-related macular degeneration (nAMD).
Methods: This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti-VEGF therapies at Sahlgrenska University Hospital between February 2024 and February 2025. Data on best-corrected visual acuity (BCVA), central retinal thickness (CRT), pigment epithelial detachment (PED) height, fluid status, treatment intervals, time to fluid recurrence and adverse events were collected.